[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453325":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":56,"collaborators":20,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":20,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MR-linac group","EXPERIMENTAL","Pts received ultra-hypofractionated RT for primary w\u002Fo adjacent oligo-metastatic diseases on 1.5-Tesla MR-Linac",[13],"Device: MR-linac",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","MR-linac","1.5-Tesla MR-linac based SBRT",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ning-Ning Lu","CONTACT","+868611804268","Ning-Ning.Lu@hotmail.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43,46,49,52,54],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":26},"Ningning Lu, Doctor","+86 01087787630",{"name":47,"role":24,"phone":20,"phoneExt":20,"email":48},"Nian-Zeng Xing, M.D.","xingnianzeng@126.com",{"name":50,"role":51,"phone":20,"phoneExt":20,"email":20},"Nian-Zeng Xing, M.D","PRINCIPAL_INVESTIGATOR",{"name":53,"role":51,"phone":20,"phoneExt":20,"email":20},"Ye-Xiong Li, M.D",{"name":55,"role":51,"phone":20,"phoneExt":20,"email":20},"Ning-Ning Lu, M.D.",{"type":51,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"NINGNING LU","Principle Investigator","100453325","mr-linac-guided-ultra-hypofractionated-rt-for-prostate-cancer-smart-p01-and-smart-p02-100453325",false,"NCT05183074","MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)","Phase II Prospective Trial of MR-linac Based Stereotactic Ablative Radiotherapy for Patients With Localized (SAMRT-P01) and Oligo-metastatic (SMART-P02) Prostate Cancer","SMART-P01\u002F02","Inclusion Criteria:\n\n* Age≥18 years。\n* Histology confirmed prostate cancer.\n* Risk stratification, localised disease including patients with low-risk(cT1-T2a，PSA \\\u003C10ng\u002FmL，Gleason score≤6) who refuse active surveillance, favorable or unfavorable intermediate-risk and selected high-risk(cT2b-T3a or minimally T3b，PSA 10-40ng\u002FmL，Gleason score 7-8) disease.\n* Oligo-metastatic disease including patients with prostate in-situ and oligometastatic disease (no limit to mets number and organs, with all metastatic foci can be safely treated by radical SBRT dose)\n* ECOG 0-2\n* Postate gland volume ≤100cc\n* IPSS score of \\\u003C18\n* Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed\n\nExclusion Criteria:\n\n* Contraindications to MRI.\n* TURP within the past 6 months\n* Ulcerative colitis, Crohn's Disease, ataxia telangiectasia, or systemic lupus erythematosus\n* Previous pelvic irradiation\n* Refuse contraception","MALE","18 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"NA","1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer\n2. To assess the acute and late toxicities, efficacy and quality of life for patients treated by MRL-SBRT\n3. To simulate the dose planning and assess the feasibility of simultaneous-boost for MR-prominent foci\n4. To investigate the relationship between the changes of blood and tissue biomarkers and manifestations on mp-MRI pre-\u002Fpost-MRL-SBRT, to further ascertain the predictive factors of local persisting and\u002For relapse disease",[77,78,79,80,81,82,83],"Prostate Cancer","Radiotherapy Side Effect","Magnetic Resonance-linac","Stereotactic Ablative RT","Adaptive Radiotherapy","Localised Disease","Oligometastatic Disease","2025-12-04",{"date":86,"type":87},"2025-12-11","ACTUAL",{"date":89,"type":87},"2021-02-01",{"date":91,"type":71},"2027-12-31",{"name":5,"class":6},1]